DISCRIMINATING DERIVATIVE SPECTROPHOTOMETRIC CONCURRENT QUANTIFICATION OF LORATADINE AND AMBROXOL IN TABLET DOSAGE FORM

Understanding the preponderance of respiratory conditions with the symptoms like sore throat and cough being even more common, owing to the coronavirus outbreak. The improved resolution method was developed to quantify drugs Loratidine and Ambroxol from the most effective dosage regimen to treat sore throat and cough. An accurate, precise method was developed for concurrently estimating drugs from combined tablet dosage form by first-order derivative UV spectrophotometric method. Absorption maxima were determined as 265 nm for Ambroxol hydrochloride (ZCP for Loratadine) and 307 nm for Loratadine (ZCP for ambroxol hydrochloride), using 0.1 N HCl as a solvent for estimation. The analysis results were developed as per ICH guidelines and the drugs obeyed beer lambert’s law in a concentration range of 10 – 125 µg/mL for Ambroxol hydrochloride and 2 – 12 µg/mL for Loratadine with a regression coefficient of 0.9994 and 0.999 respectively. The %RSD values (<2) in precision studies indicate the method’s reproducibility. The LOD values were found to be 1.35µg/ml and 0.37µg/mL, and LOQ values were found to be 3.13µg/mL and 1.15µg/mL for Ambroxol hydrochloride and Loratadine, respectively. The simple and easy method can be applied for routine drug analysis in pharmaceutical quality control and biological samples.